Late-stage biotech Relypsa raises deal size to $138 million

By Renaissance Capital,

Shutterstock photo

Relypsa, a late-stage biotech developing treatments for renal, cardiovascular and metabolic diseases, raised its deal size to $138 million and announced it will list under the ticker RLYP on Thursday. The Redwood City, CA-based company had previously filed to raise up to $127 million.

Relypsa was founded in 2007 and plans to list on the NASDAQ. The company initially filed confidentially on August 2, 2013. Morgan Stanley and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks:

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by